CDT Equity Inc. (CDT)
NASDAQ: CDTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Pre-market: 0.7903 -1.21%
CDT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $32.43K
- P/E (TTM)
- 0.00
- EPS (TTM)
- $90,812.50
- Dividend yield
- None
- 52-week range
- 0.796 – 28,400.00
- Day range
- 0.796 – 0.8509
- Volume / Avg
- 247.67K / 188.27K
- Beta
- —
- Shares outstanding
- 40.54K
52-week range
CDT stock today
CDT Equity (CDT) closed at $0.80 on Oct 8, down 4.31% (-$0.036), versus the S&P 500's 0.47% decline. Shares are 100.0% below their 52-week high of $28,400.00 and 0.5% above the 52-week low of $0.796, near the bottom of the past year's range. CDT Equity trades at 0.0x its trailing twelve-month earnings per share of $90,812.50.
Summary generated from market data by MetaCap's automated system. Methodology
About CDT Equity
Company profileCDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. James Bligh
- Headquarters
- Naples, FL
- Employees
- 4
- IPO year
- 2022
- Website
- cdtequity.com
CDT Equity peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PBMPsyence Biomedical Ltd. | 5.12 | +4.28% | — | vs CDT |
| SXTCChina SXT Pharmaceuticals Inc. Class A | 0.3435 | -87.86% | $453.91K | vs CDT |
| DCOYDecoy Therapeutics Inc. | 1.52 | -5.59% | $995.88K | vs CDT |
| BDRXBiodexa Pharmaceuticals plc American Depositary Shs | 0.5237 | -7.11% | $1.15M | vs CDT |
| ARTLArtelo Biosciences Inc. | 3.37 | -1.17% | $1.85M | vs CDT |
| SBFMSunshine Biopharma Inc. | 0.43 | -38.57% | $1.85M | vs CDT |
| LABTLakewood-Amedex Biotherapeutics Inc. | 0.792 | -6.80% | $1.88M | vs CDT |
| OGENOragenics Inc. | 0.463 | -7.38% | $2.09M | vs CDT |
Indexes, lists and sector
CDT Equity stock FAQ
What is CDT Equity's stock price today?
CDT last traded at $0.80 as of Oct 8, 4:00 PM EDT, down 4.31% on the day. Prices are delayed at least 15 minutes.
What is CDT's P/E ratio?
CDT trades at a trailing P/E ratio of 0.00.
Who is CDT Equity's CEO?
Mr. James Bligh is the chief executive officer of CDT Equity Inc., which has about 4 employees.
What is the CDT 52-week high?
The 52-week high for CDT is $28,400.00 and the 52-week low is $0.796. The stock is currently 100.0% below its high.